Trials / Completed
CompletedNCT01279473
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
A Phase I/II Multicenter, Dose-escalation Study of Oral Nilotinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ALL (Philadelphia Positive Acute Lymphocytic Leukemia)(Extension Study)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nilotinib |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2009-12-01
- First posted
- 2011-01-19
- Last updated
- 2020-12-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01279473. Inclusion in this directory is not an endorsement.